Dr. Kelley on Newly Approved Agents in HCC

R. Kate Kelley
Published: Thursday, Mar 15, 2018



R. Kate Kelley, MD, associate professor of clinical medicine, Department of Medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the clinical impact of REFLECT and CELESTIAL in hepatocellular carcinoma (HCC).

After the approval of sorafenib (Nexavar), there was a string of negative trials in HCC. Last year, 4 other HCC agents were reported in positive trials. In 2017, 2 drugs were approved in addition to sorafenib. Regorafenib (Stivarga) was approved as a second-line agent, and nivolumab (Opdivo) was approved after first-line sorafenib.

In early 2018, the REFLECT and CELESTIAL trials reported positive findings. REFLECT examined the use of frontline lenvatinib (Lenvima) and showed noninferiority to sorafenib. At the 2018 Gastrointestinal Cancers Symposium, CELESTIAL reported a benefit in the use of second- or third-line cabozantinib (Cabometyx) following sorafenib. All of a sudden, Kelley says, physicians have to navigate a very complex landscape.

Now, the wildcard is nivolumab, which has the potential to change the landscape even further.
 
SELECTED
LANGUAGE


R. Kate Kelley, MD, associate professor of clinical medicine, Department of Medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the clinical impact of REFLECT and CELESTIAL in hepatocellular carcinoma (HCC).

After the approval of sorafenib (Nexavar), there was a string of negative trials in HCC. Last year, 4 other HCC agents were reported in positive trials. In 2017, 2 drugs were approved in addition to sorafenib. Regorafenib (Stivarga) was approved as a second-line agent, and nivolumab (Opdivo) was approved after first-line sorafenib.

In early 2018, the REFLECT and CELESTIAL trials reported positive findings. REFLECT examined the use of frontline lenvatinib (Lenvima) and showed noninferiority to sorafenib. At the 2018 Gastrointestinal Cancers Symposium, CELESTIAL reported a benefit in the use of second- or third-line cabozantinib (Cabometyx) following sorafenib. All of a sudden, Kelley says, physicians have to navigate a very complex landscape.

Now, the wildcard is nivolumab, which has the potential to change the landscape even further.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Rapid Reviews in Oncology®: Practice-Changing Data in Acute Myeloid Leukemia: A Rapid Update From Atlanta OnlineDec 21, 20182.0
Community Practice Connections™: 2nd Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesDec 30, 20182.0
Publication Bottom Border
Border Publication
x